Soluble ST2: A Novel Biomarker for Diagnosis and Prognosis of Cardiovascular Disease

Overview

Journal Curr Med Sci

Specialty General Medicine

Date 2024 Aug 3

PMID 39096477

Authors

Yin Feng

Li-Qun He

Affiliations

Soon will be listed here.

Abstract

The increasing incidence of cardiovascular disease (CVD) is a significant global health concern, affecting millions of individuals each year. Accurate diagnosis of acute CVD poses a formidable challenge, as misdiagnosis can significantly decrease patient survival rates. Traditional biomarkers have played a vital role in the diagnosis and prognosis of CVDs, but they can be influenced by various factors, such as age, sex, and renal function. Soluble ST2 (sST2) is a novel biomarker that is closely associated with different CVDs. Its low reference change value makes it suitable for continuous measurement, unaffected by age, kidney function, and other confounding factors, facilitating risk stratification of CVDs. Furthermore, the combination of sST2 with other biomarkers can enhance diagnostic accuracy and prognostic value. This review aims to provide a comprehensive overview of sST2, focusing on its diagnostic and prognostic value as a myocardial marker for different types of CVDs and discussing the current limitations of sST2.

Citing Articles

Targeting IL-33 in patients with cancer under immune checkpoint inhibitors for a better antitumor response and prevent thromboembolism?.

Azzellino G, Ginaldi L, De Martinis M J Immunother Cancer. 2025; 13(2).

PMID: 39915265 PMC: 11804193. DOI: 10.1136/jitc-2024-010806.

References

Zhao D, Liu J, Wang M, Zhang X, Zhou M . Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2018; 16(4):203-212. DOI: 10.1038/s41569-018-0119-4. View

Bayes-Genis A, De Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R . Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2011; 14(1):32-8. DOI: 10.1093/eurjhf/hfr156. View

Villacorta H, Maisel A . Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure. Arq Bras Cardiol. 2016; 106(2):145-52. PMC: 4765013. DOI: 10.5935/abc.20150151. View

Daniels L, Clopton P, Iqbal N, Tran K, Maisel A . Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J. 2010; 160(4):721-8. DOI: 10.1016/j.ahj.2010.06.033. View

Pascual-Figal D, Ordonez-Llanos J, Tornel P, Vazquez R, Puig T, Valdes M . Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009; 54(23):2174-9. DOI: 10.1016/j.jacc.2009.07.041. View

Gawor M, Spiewak M, Janas J, Kozuch K, WrOBel A, Mazurkiewicz L . The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol Pol. 2017; 75(10):997-1004. DOI: 10.5603/KP.a2017.0118. View

Kakkar R, Lee R . The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7(10):827-40. PMC: 4277436. DOI: 10.1038/nrd2660. View

Mueller T, Jaffe A . Soluble ST2--analytical considerations. Am J Cardiol. 2015; 115(7 Suppl):8B-21B. DOI: 10.1016/j.amjcard.2015.01.035. View

Homsak E, Gruson D . Soluble ST2: A complex and diverse role in several diseases. Clin Chim Acta. 2020; 507:75-87. DOI: 10.1016/j.cca.2020.04.011. View

10.

Ragusa R, Prontera C, Di Molfetta A, Cabiati M, Masotti S, Del Ry S . Time-course of circulating cardiac and inflammatory biomarkers after Ventricular Assist Device implantation: Comparison between paediatric and adult patients. Clin Chim Acta. 2018; 486:88-93. DOI: 10.1016/j.cca.2018.07.036. View

11.

Morello F, Bartalucci A, Bironzo M, Santoro M, Pivetta E, Ianniello A . Prospective diagnostic accuracy study of plasma soluble ST2 for diagnosis of acute aortic syndromes. Sci Rep. 2020; 10(1):3103. PMC: 7033105. DOI: 10.1038/s41598-020-59884-6. View

12.

Tominaga S . A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989; 258(2):301-4. DOI: 10.1016/0014-5793(89)81679-5. View

13.

Pascual-Figal D, Januzzi J . The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl):3B-7B. DOI: 10.1016/j.amjcard.2015.01.034. View

14.

Iwahana H, Yanagisawa K, Kuroiwa K, Tago K, Komatsu N, Katashima R . Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. 1999; 264(2):397-406. DOI: 10.1046/j.1432-1327.1999.00615.x. View

15.

Weinberg E, Shimpo M, De Keulenaer G, Macgillivray C, Tominaga S, Solomon S . Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23):2961-6. PMC: 1460012. DOI: 10.1161/01.cir.0000038705.69871.d9. View

16.

Schmitter D, Cotter G, Voors A . Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev. 2013; 19(3):369-81. DOI: 10.1007/s10741-013-9396-5. View

17.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan T . IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23(5):479-90. DOI: 10.1016/j.immuni.2005.09.015. View

18.

De la Fuente M, Macdonald T, Hermoso M . The IL-33/ST2 axis: Role in health and disease. Cytokine Growth Factor Rev. 2015; 26(6):615-23. DOI: 10.1016/j.cytogfr.2015.07.017. View

19.

Vianello E, Dozio E, Tacchini L, Frati L, Corsi Romanelli M . ST2/IL-33 signaling in cardiac fibrosis. Int J Biochem Cell Biol. 2019; 116:105619. DOI: 10.1016/j.biocel.2019.105619. View

20.

Weinberg E . ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomark Med. 2010; 3(5):495-511. DOI: 10.2217/bmm.09.56. View